Microbiotica CEO on £36m raise to advance gut treatment into Phase 2; IP Group invests £4m

Podcast: Proactive - Interviews for investors · Proactive

Opublikowano: 2026-10-21

Microbiotica CEO Tim Sharpington spoke with Proactive's Stephen Gunnion about the company’s £36 million Series C funding round and plans to advance its lead treatment for ulcerative colitis into Phase 2 clinical trials. Microbiotica, an IP Group PLC (LSE:IPO) portfolio company, develops oral medicines based on the gut microbiome, using its proprietary genomics-driven platform to identify bacterial strains associated with positive clinical outcomes. The latest funding will support the development of MB310, a once-daily capsule containing eight specific gut bacterial strains designed to repair the intestinal barrier and reduce inflammation. Sharpington highlighted encouraging Phase 1b results from the COMPOSER-1 study, whi...